The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Venetoclax monotherapy in MCL: longer-term results
Matthew Davids, MD, MSc, of Dana-Farber Cancer Institute, Boston, MA, discusses the results from the longer-term follow-up of mantle cell lymphoma (MCL) patients treated with venetoclax monotherapy (NCT01328626), now with a median of 27 months, which he presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA. Dr Davids then gives his insight into the future directions for the use of venetoclax in MCL.
